Dysregulation of KRAS signaling in pancreatic cancer is not
associated with KRAS mutations and outcome

J 2017

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome

LEMSTROVA, Radmila, Veronika BRYNYCHOVA, David J. HUGHES, Viktor HLAVAS, Pavel DVORAK et. al.

Basic information

Original name

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome

Authors

LEMSTROVA, Radmila (203 Czech Republic), Veronika BRYNYCHOVA (203 Czech Republic), David J. HUGHES (372 Ireland), Viktor HLAVAS (203 Czech Republic), Pavel DVORAK (203 Czech Republic), Joanne E. DOHERTY (372 Ireland), Helena A. MURRAY (372 Ireland), Martin CROCKARD (372 Ireland), martin OLIVERIUS (203 Czech Republic), Jan HLAVSA (203 Czech Republic, guarantor, belonging to the institution), Eva HONSOVA (203 Czech Republic), Jan MAZANEC (203 Czech Republic, belonging to the institution), Zdeněk KALA (203 Czech Republic, belonging to the institution), Martin LOVECEK (203 Czech Republic), Roman HAVLIK (203 Czech Republic), Jiri EHRMANN (203 Czech Republic), Ondrej STROUHAL (203 Czech Republic), Pavel SOUCEK (203 Czech Republic), Bohuslav MELICHAR (203 Czech Republic) and Beatrice MOHELNIKOVA-DUCHONOVA (203 Czech Republic)

Edition

Oncology Letters, Athens, SPANDIDOS PUBL LTD, 2017, 1792-1074

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Greece

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.664

RIV identification code

RIV/00216224:14110/17:00097981

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3892/ol.2017.6946

UT WoS

000415083000127

Keywords in English

pancreatic ductal adenocarcinoma; KRAS; gene expression; mutation; overall survival

Abstract

V originále

Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, and no targeted therapy is currently available. The aim of the present study was to investigate the prognostic significance of the expression of V-Ki-ras2 kirsten rat sarcoma viral oncogene homolog (KRAS), downstream signaling pathway genes and the association with clinical characteristics in PDAC patients undergoing radical surgery. Tumors and adjacent non-neoplastic pancreatic tissues were examined in 45 patients with histologically verified PDAC. KRAS and B-Raf proto-oncogene, serine/threonine kinase (BRAF) gene mutation analysis was performed using the KRAS/BRAF/phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha array.

Citovat

LEMSTROVA, Radmila, Veronika BRYNYCHOVA, David J. HUGHES, Viktor HLAVAS, Pavel DVORAK, Joanne E. DOHERTY, Helena A. MURRAY, Martin CROCKARD, martin OLIVERIUS, Jan HLAVSA, Eva HONSOVA, Jan MAZANEC, Zdeněk KALA, Martin LOVECEK, Roman HAVLIK, Jiri EHRMANN, Ondrej STROUHAL, Pavel SOUCEK, Bohuslav MELICHAR and Beatrice MOHELNIKOVA-DUCHONOVA. Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. Oncology Letters. Athens: SPANDIDOS PUBL LTD, 2017, vol. 14, No 5, p. 5980-5988. ISSN 1792-1074. Available from: https://dx.doi.org/10.3892/ol.2017.6946.

@article{1393056,
   author = {Lemstrova, Radmila and Brynychova, Veronika and Hughes, David J. and Hlavas, Viktor and Dvorak, Pavel and Doherty, Joanne E. and Murray, Helena A. and Crockard, Martin and Oliverius, martin and Hlavsa, Jan and Honsova, Eva and Mazanec, Jan and Kala, Zdeněk and Lovecek, Martin and Havlik, Roman and Ehrmann, Jiri and Strouhal, Ondrej and Soucek, Pavel and Melichar, Bohuslav and MohelnikovaandDuchonova, Beatrice},
   article_location = {Athens},
   article_number = {5},
   doi = {http://dx.doi.org/10.3892/ol.2017.6946},
   keywords = {pancreatic ductal adenocarcinoma; KRAS; gene expression; mutation; overall survival},
   language = {eng},
   issn = {1792-1074},
   journal = {Oncology Letters},
   title = {Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome},
   volume = {14},
   year = {2017}
}

TY  - JOUR
ID  - 1393056
AU  - Lemstrova, Radmila - Brynychova, Veronika - Hughes, David J. - Hlavas, Viktor - Dvorak, Pavel - Doherty, Joanne E. - Murray, Helena A. - Crockard, Martin - Oliverius, martin - Hlavsa, Jan - Honsova, Eva - Mazanec, Jan - Kala, Zdeněk - Lovecek, Martin - Havlik, Roman - Ehrmann, Jiri - Strouhal, Ondrej - Soucek, Pavel - Melichar, Bohuslav - Mohelnikova-Duchonova, Beatrice
PY  - 2017
TI  - Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome
JF  - Oncology Letters
VL  - 14
IS  - 5
SP  - 5980-5988
EP  - 5980-5988
PB  - SPANDIDOS PUBL LTD
SN  - 17921074
KW  - pancreatic ductal adenocarcinoma
KW  - KRAS
KW  - gene expression
KW  - mutation
KW  - overall survival
N2  - Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, and no targeted therapy is currently available. The aim of the present study was to investigate the prognostic significance of the expression of V-Ki-ras2 kirsten rat sarcoma viral oncogene homolog (KRAS), downstream signaling pathway genes and the association with clinical characteristics in PDAC patients undergoing radical surgery. Tumors and adjacent non-neoplastic pancreatic tissues were examined in 45 patients with histologically verified PDAC. KRAS and B-Raf proto-oncogene, serine/threonine kinase (BRAF) gene mutation analysis was performed using the KRAS/BRAF/phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha array.
ER  -

LEMSTROVA, Radmila, Veronika BRYNYCHOVA, David J. HUGHES, Viktor HLAVAS, Pavel DVORAK, Joanne E. DOHERTY, Helena A. MURRAY, Martin CROCKARD, martin OLIVERIUS, Jan HLAVSA, Eva HONSOVA, Jan MAZANEC, Zdeněk KALA, Martin LOVECEK, Roman HAVLIK, Jiri EHRMANN, Ondrej STROUHAL, Pavel SOUCEK, Bohuslav MELICHAR and Beatrice MOHELNIKOVA-DUCHONOVA. Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. \textit{Oncology Letters}. Athens: SPANDIDOS PUBL LTD, 2017, vol.~14, No~5, p.~5980-5988. ISSN~1792-1074. Available from: https://dx.doi.org/10.3892/ol.2017.6946.

Detailed Information on Publication Record